PARADIGM BIOPHARMACEUTICALS LIMITED (PAR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PAR - PARADIGM BIOPHARMACEUTICALS LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.90

21 Oct
2021

-0.060

OPEN

$1.93

-3.06%

HIGH

$1.96

322,434

LOW

$1.89

TARGET
$1.68 -11.6% downside
OTHER COMPANIES IN THE SAME SECTOR
CUV . ACR . AHZ . CSL . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . ADO . PYC . RAC . RCE . ZNO . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . OPT . ANP .
FNARENA'S MARKET CONSENSUS FORECASTS
PAR: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx - 16.7 - 15.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx-16.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx34.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-34.9 M
Net Profit Margin xxxxxxxxxxxxxxx-166,896.27 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx-36.79 %
Return on Invested Capital xxxxxxxxxxxxxxx-36.52 %
Return on Assets xxxxxxxxxxxxxxx-34.79 %
Return on Equity xxxxxxxxxxxxxxx-36.79 %
Return on Total Capital xxxxxxxxxxxxxxx-45.03 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-35.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

30/08/2021

3

Upgrade to Hold from Reduce

$1.68

-11.58%

Paradigm Biopharmaceuticals reported its FY21 result with net losses increasing as regulatory programs progress, but there were major surprises on this front given quarterly reporting. 

The company's largely in-line result was aided by a difference in R&D rebate treatment with the company recognising its expected rebate in FY21.

While there are clearly some major upcoming catalysts, which are likely to increase volatility and may present a short-term trading opportunity, over the long term Morgans continues to see risks to the downside around narrower marketability and higher competition than consensus suggests.

Morgans upgrades the company to Hold from Reduce and lowers the target price to $1.68 from $1.69.

FORECAST
Morgans forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -15.00 cents.
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -24.00 cents.

PAR STOCK CHART